qfx

I spent a good hour trying to decipher the SEC filing, which, as far as I can tell, is designed to be read only by lawyers and masochists. Apparently, this wasn’t a panicked, fire-sale kind of transaction. Mr. Link had a plan. A Rule 10b5-1 trading plan, to be exact. It sounds like a tax code section, doesn’t it? All very responsible. He set it up in December, presumably while everyone else was busy battling relatives and pretending to enjoy eggnog. It’s the kind of foresight I lack. I usually only plan things like what flavor of instant ramen to buy.

The hope now rests with the R2, a new line of SUVs intended to broaden the reach of this electric vehicle maker. It’s a simple equation, really: more vehicles, more revenue. But the market isn’t built on simple equations. It’s a living thing, breathing and shifting, and demands a deeper look before a man commits his capital.

The filing with the Securities and Exchange Commission reveals a reduction in Vestal Point’s stake, a lessening of its embrace. The quarter-end position, diminished by $90.50 million, reflects not only the sale of shares, but the inevitable ebb and flow of market valuation. One observes a certain…prudence in this action, a quiet acknowledgment that even the most carefully cultivated gardens require periodic pruning.

Old Man Walmart, a rather portly fellow, has a knack for surviving these downturns. In fact, he positively grows when times are tough. During the last three big scrapes – the COVID kerfuffle, the Great Recession, and that dot-com fizzle – his shares did rather nicely. Folks, when their pockets are feeling a bit light, they don’t go seeking fancy truffles. They head for the sensible staples. And that’s where Walmart excels.

The aforementioned Vestal Point, in a filing with the Securities and Exchange Commission – a document as dry as a summer’s dust – revealed this acquisition. One can almost picture the scribes diligently recording the transaction, oblivious to the spectacle they were documenting. The value of this holding, at the quarter’s end, amounted to the aforementioned $181.80 million. A considerable wager, even in these inflationary times.

The aforementioned Cormorant, in a filing dated February 17th, 2026, decided to bolster its holdings in MoonLake, a company that’s been causing a bit of a stir in the medical world. This wasn’t merely a casual dip of the toe; it was a full-blown plunge, adding a considerable sum to their portfolio. The position, we’re told, swelled by a further $43.11 million, a figure that accounts for both the acquisition of shares and the rather pleasing upward trajectory of the share price itself.

The stock’s been bouncing around like a pinball in a seizure, sure. Up, down, sideways, fueled by the AI hype machine. They’re boasting about growth, naturally. 168% revenue jump? Sounds impressive until you realize it’s just chasing its own tail in a rapidly inflating bubble. The fools are already pricing in miracles, I tell you. MIRACLES.

The market, a rather excitable beast at the best of times, promptly snapped up Circle’s stock, sending it bouncing about like a rubber ball. More than 9% higher, they say. All because of a digital promise, a bit like believing in fairies, if you ask me.